Polymed Biopharmaceuticals is focused on creating optimized PROTACs and Degrader Antibody Conjugates (DACs) with a superior therapeutic index than 1st generation PROTACs.  Polymed leverages advanced technologies plus deep expertise in PROTAC and DAC design to create novel assets with optimized therapeutic properties delivering the next generation of life-changing medicines to patients with cancer and autoimmune disorders worldwide. Polymed is based in Hangzhou, China, and Cambridge, Massachusetts, and is a member of the Johnson and Johnson JLABS Innovation network.
www.polymedbiopharma.com
Website: www.bsppharmaceuticals.com
